Type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: receiving one pill containing 100 mg powder of Saffron daily with meal for 3 months. Intervention 2: Control group: receiving one pill containing 100 mg maltode
Treatment - Drugs
Placebo
Intervention group: receiving one pill containing 100 mg powder of Saffron daily with meal for 3 months.
Control group: receiving one pill containing 100 mg maltodextrin daily with meal for 3 months.
Sponsors
Vice-chancellor for research Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with type 2 Diabetes; 30-70 years ages; diabetes patients with oral medication intake; not Smoking and Alcohol intake; Hb A1C: 7-10 % ; BMI between 20-35; no Pregnancy and Lactation; not consumption of antioxidants , multivitamins and omega 3 supplements from 3 months ago; do not taking the lipid and blood pressure- lowering drugs ; not consumption contraceptives and insulin therapy. Exclusion criteria: unwillingness to continue cooperation; taking less than 80% of supplements(the compliance lower than %80); changes in Diet or Physical activity; changes in type or dose of medication; renal, hepatic, thyroid and Parathyroid disorders.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c. Timepoint: Before intervention and three months after intervention. Method of measurement: ELISA.;FBS. Timepoint: Before intervention and three months after intervention. Method of measurement: Enzymatic method.;Insulin. Timepoint: Before intervention and three months after intervention. Method of measurement: ELISA.;Total cholesterol. Timepoint: Before intervention and three months after intervention. Method of measurement: Enzymatic method.;Triglyceride. Timepoint: Before intervention and three months after intervention. Method of measurement: Enzymatic method.;LDL. Timepoint: Before intervention and three months after intervention. Method of measurement: Enzymatic method.;HDL. Timepoint: Before intervention and three months after intervention. Method of measurement: Enzymatic method.;Systolic blood pressure. Timepoint: Before intervention and three months after intervention. Method of measurement: Mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Before intervention and three months after intervention. Method of measurement: Mercury sphygmomanometer.;MDA(Malondialdehyde). Timepoint: Before intervention and three months after intervention. Method of measurement: Spectrophotometry method.;Hs-CRP. Timepoint: Before intervention and three months after intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before intervention and three months after intervention. Method of measurement: ELISA.;TAC(Total antioxidant capacity). Timepoint: Before intervention and three months after intervention. Method of measurement: Spectrophotometry method.;BMI(Body mass index). Timepoint: Before intervention and three months after intervention. Method of measurement: Weight (kg)/[height (m)]2, kg/m2.;Age. Timepoint: Before intervention. Method of measurement: questionnaire.;Weight. Timepoint: Before intervention and three months after intervention. Method of measurement: Scale.;Sex. Timepoint: Before intervention. Method of measurement: questionnaire.;Height | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Nahid Aryaeian
Iran University of Medical Sciences
Outcome results
None listed